Compare NRG Energy Inc (NRG) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NRG Energy Inc vs Novo Nordisk A/S — how do they compare? NRG Energy Inc trades at $121.21 (market cap $24.83B), while Novo Nordisk A/S trades at $46.28 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 8.4× NRG Energy Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| NRG | NVO | |
|---|---|---|
Market Cap | $24.83B | $207.85B |
Sector | Utilities | Health |
52-Week High | $184.03 | $63.98 |
52-Week Low | $117.04 | $35.29 |
Enterprise Value | $48.79B | $222.55B |
Dividend Yield | 1.61% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NRG Energy trades at $120.37, down 1.23% with a bearish technical signal. Recent Q2 2026 earnings missed estimates at $1.49 EPS versus $1.69 expected, though revenue grew 11% year-over-year. The company is advancing a 1.2 GW Texas data-center power project to capitalize on AI-driven electricity demand, supported by a 69% analyst buy rating and a $207.83 consensus price target. Cash flow from operations was $1.91B in 2025, but net income margin compressed to 2.56%.
Outlook is mixed: growth initiatives in data center power present upside, but execution risks and rising interest costs pressure margins. The stock offers a 1.6% dividend yield, yet high debt-to-asset ratio of 56.42% in 2025 warrants caution. Near-term support lies at $119, with resistance at $122.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
